Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist
← catalyst calendarNCT07718724 · readout in 619 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Other
Enrollment
540estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-15 | estimated | When the study began enrolling |
| Primary completion | 2028-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Uncontrolled Asthma
Intervention
- Behavioral: Intervention group
Primary outcomes
what the primary-completion date above is the date OFDifference in the proportion of participants with a written diagnosis of "Severe Asthma" between the intervention and control groups at Week 24
measured Week 24
Difference in the annualized asthma exacerbation rate between the intervention and control groups at Week 48
measured Week 48
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed